{"ATC Code":"A07DA03","Abbreviation":"","Aliases":["Loperamida","Ioperamide","Loperamidum","Loperamide","4-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)-N,N-dimethyl-2,2-diphenylbutanamide","4-(4-Chlorophenyl)-N,N-dimethyl-alpha,alpha-diphenyl-4-hydroxy-1-piperidinebutanamide","EC 258-416-5","5-21-02-00379 (Beilstein Handbook Reference)","Fortasec","1-Piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-N,N-dimethyl-alpha,alpha-diphenyl-"],"Biological Half-Life":"The apparent elimination half-life of loperamide is 10.8 hours with a range of 9.1 to 14.4 hours.","CAS":"53179-11-6","ChEBI":"CHEBI:6532","ChEMBL":"CHEMBL841","ChemicalClasses":["piperidine"],"Chirality":"achiral","Drug Classes":"Breast Feeding; Lactation; Milk, Human; Antidiarrheals; Gastrointestinal Agents","Drug Indication":"Loperamide is indicated for the relief of diarrhea, including Travelers’ Diarrhea. As an off-label use, it is often used to manage chemotherapy-related diarrhea.","Drug Warnings":"Loperamide is generally well tolerated; however, abdominal pain, distention or discomfort, constipation, drowsiness, dizziness, fatigue, dry mouth, nausea and vomiting, and epigastric pain may occur. Children may be more sensitive to adverse CNS effects of the drug than adults. Hypersensitivity reactions including rash have been reported. Adverse effects of loperamide are difficult to distinguish from symptoms associated with the diarrheal syndrome, but adverse GI effects are reported to be less frequent after administration of loperamide than after administration of diphenoxylate with atropine. In postmarketing experiences, paralytic ileus associated with abdominal distention has been reported rarely. Most of these cases occurred in patients with acute dysentery, following overdosage of the drug, or in children younger than 2 years of age.","DrugClasses":["opioid"],"EINECS":"258-416-5","European Community (EC) Number":"258-416-5","FDA Pharmacological Classification":"6X9OC3H4II","Human Drugs":"Breast Feeding; Lactation; Milk, Human; Antidiarrheals; Gastrointestinal Agents","IUPACName":"4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide","InChI":"InChI=1S/C29H33ClN2O2/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32-20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3","InChIKey":"RDOIQAHITMMDAJ-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Miscellaneous agents found useful in the symptomatic treatment of diarrhea. They have no effect on the agent(s) that cause diarrhea, but merely alleviate the condition. (See all compounds classified as Antidiarrheals.)","Melting Point":"220-228","MolecularFormula":"C\u003csub\u003e29\u003c/sub\u003eH\u003csub\u003e33\u003c/sub\u003eClN\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003e","MolecularWeight":"477.0 g/mol","Pharmacodynamics":"Loperamide is an anti-diarrheal agent that provides symptomatic relief of diarrhea. It decreases peristalsis and fluid secretion in the gastrointestinal tract, delays colonic transit time, and increases the absorption of fluids and electrolytes from the gastrointestinal tract. Loperamide also increases rectal tone, reduces daily fecal volume, and increases the viscosity and bulk density of feces. It also increases the tone of the anal sphincter, thereby reducing incontinence and urgency. The onset of action is about one hour and the duration of action can be up to three days.  While loperamide is a potent mu-opioid receptor agonist, it does not mediate significant analgesic activity at therapeutic and supratherapeutic doses. However, at high doses of loperamide, inhibition of P-glycoprotein-mediated drug efflux may allow loperamide to cross the blood-brain barrier, where loperamide can exert central opioid effects and toxicity.  At very high plasma concentrations, loperamide can interfere with cardiac conduction. Because loperamide inhibits the Na\u003csup\u003e+\u003c/sup\u003e-gated cardiac channels and ether-a-go-go–related gene potassium channels, the drug can prolong the QRS complex and the QTc interval, which can lead to ventricular dysrhythmias, monomorphic and polymorphic ventricular tachycardia, torsade de pointes, ventricular fibrillation, Brugada syndrome, cardiac arrest, and death.","Physical Description":"Solid","PubChemId":3955,"Record Description":["Loperamide is a synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease. It has a role as a mu-opioid receptor agonist, an antidiarrhoeal drug and an anticoronaviral agent. It is a member of piperidines, a monocarboxylic acid amide, a member of monochlorobenzenes and a tertiary alcohol. It is a conjugate base of a loperamide(1+).","Loperamide is an anti-diarrheal agent that is available as an over-the-counter product for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that works by binding to mu-opioid receptors on intestinal muscles to decrease intestinal motility and electrolyte loss. Loperamide has a chemical structure that is similar to diphenoxylate and haloperidol; however, loperamide works on mu (μ)-opioid receptors to mediate its pharmacological actions.","Loperamide is an Opioid Agonist. The mechanism of action of loperamide is as an Opioid Agonist.","Loperamide is synthetic opioid that primarily affects opiate receptors in the intestine and is used to treat diarrhea. Loperamide has not been linked to serum enzyme elevations during therapy or to clinically apparent liver injury.","Loperamide is a synthetic agent chemically related to the opiates with anti-diarrheal properties.  Loperamide decreases gastro-intestinal motility by effects on the circular and longitudinal muscles of the intestine. Part of its anti-diarrheal effect may be due to a reduction of gastro-intestinal secretion produced by opioid receptor binding in the intestinal mucosa. (NCI04)","LOPERAMIDE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for diarrhea and has 12 investigational indications.","One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.","See also: Loperamide Hydrochloride (has salt form).","Loperamide is a synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease. It has a role as a mu-opioid receptor agonist, an antidiarrhoeal drug and an anticoronaviral agent. It is a member of piperidines, a monocarboxylic acid amide, a member of monochlorobenzenes and a tertiary alcohol. It is a conjugate base of a loperamide(1+).","LiverTox|Gastroinestinal|Diarrhea|Opiate"],"References":[{"name":"Wikipedia","url":"https://en.wikipedia.org/wiki/Loperamide"},{"name":"Wikidata","url":"https://www.wikidata.org/wiki/Q423751"},{"name":"DrugBank","url":"https://go.drugbank.com/drugs/DB00836"},{"name":"PubChem","url":"https://pubchem.ncbi.nlm.nih.gov/compound/3955"},{"name":"ChemSpider","url":"https://www.chemspider.com/Chemical-Structure.3818.html"},{"name":"ChEMBL","url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL841"},{"name":"ChEBI","url":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6532"},{"name":"Common Chemistry","url":"https://commonchemistry.cas.org/detail?cas_rn=53179-11-6"},{"name":"HMDB","url":"https://hmdb.ca/metabolites/HMDB0004999"},{"name":"KEGG","url":"https://www.kegg.jp/entry/C07080"},{"name":"UNII","url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/6X9OC3H4II"},{"name":"EPA DSSTox","url":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID6045165"}],"SMILES":"CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4","Salts":["hydrochloride"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="86.711mm" version="1.2" viewBox="0 0 162.988 86.711" width="162.988mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#FF0D0D" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="87.0" stroke="none" width="163.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="36.396" x2="41.901" y1="85.673" y2="76.137"/>
                  
            <line class="bond" id="mol1bnd2" x1="47.357" x2="59.256" y1="72.475" y2="72.475"/>
                  
            <line class="bond" id="mol1bnd3" x1="41.901" x2="36.396" y1="68.813" y2="59.277"/>
                  
            <g class="bond" id="mol1bnd4">
                        
                <line x1="37.1" x2="24.815" y1="60.496" y2="60.496"/>
                        
                <line x1="37.1" x2="24.815" y1="58.058" y2="58.058"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="24.815" x2="30.957500000000003" y1="60.496" y2="60.496"/>
                <line class="hi" stroke="#FF0D0D" x1="24.815" x2="30.957500000000003" y1="58.058" y2="58.058"/>
            </g>
                  
            <line class="bond" id="mol1bnd5" x1="36.396" x2="44.016" y1="59.277" y2="46.079"/>
                  
            <line class="bond" id="mol1bnd6" x1="44.016" x2="59.256" y1="46.079" y2="46.079"/>
                  
            <line class="bond" id="mol1bnd7" x1="59.256" x2="66.876" y1="46.079" y2="32.88"/>
                  
            <line class="bond" id="mol1bnd8" x1="66.876" x2="78.775" y1="32.88" y2="32.88"/>
                  
            <line class="bond" id="mol1bnd9" x1="84.229" x2="89.736" y1="29.218" y2="19.672"/>
                  
            <line class="bond" id="mol1bnd10" x1="89.736" x2="104.976" y1="19.672" y2="19.672"/>
                  
            <line class="bond" id="mol1bnd11" x1="104.976" x2="112.596" y1="19.672" y2="32.88"/>
                  
            <line class="bond" id="mol1bnd12" x1="112.596" x2="104.976" y1="32.88" y2="46.088"/>
                  
            <line class="bond" id="mol1bnd13" x1="104.976" x2="89.736" y1="46.088" y2="46.088"/>
                  
            <line class="bond" id="mol1bnd14" x1="84.229" x2="89.736" y1="36.543" y2="46.088"/>
                  
            <line class="bond" id="mol1bnd15" x1="112.596" x2="124.271" y1="32.88" y2="42.675"/>
                  
            <g class="bond" id="mol1bnd16">
                        
                <line x1="124.271" x2="121.676" y1="42.675" y2="57.523"/>
                        
                <line x1="126.43" x2="124.319" y1="44.486" y2="56.566"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd17" x1="121.676" x2="133.303" y1="57.523" y2="67.376"/>
                  
            <g class="bond" id="mol1bnd18">
                        
                <line x1="133.303" x2="147.601" y1="67.376" y2="62.448"/>
                        
                <line x1="133.82" x2="145.454" y1="64.619" y2="60.609"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd19" x1="147.601" x2="150.316" y1="62.448" y2="47.302"/>
                  
            <g class="bond" id="mol1bnd20">
                        
                <line x1="150.316" x2="138.69" y1="47.302" y2="37.448"/>
                        
                <line x1="147.668" x2="138.192" y1="48.254" y2="40.223"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd21" x1="124.271" x2="138.69" y1="42.675" y2="37.448"/>
                  
            <line class="bond" id="mol1bnd22" x1="147.601" x2="156.544" y1="62.448" y2="70.105"/>
                  
            <line class="bond" id="mol1bnd23" x1="112.596" x2="121.303" y1="32.88" y2="25.576"/>
                  
            <line class="bond" id="mol1bnd24" x1="44.016" x2="46.662" y1="46.079" y2="31.07"/>
                  
            <g class="bond" id="mol1bnd25">
                        
                <line x1="34.978" x2="46.662" y1="21.272" y2="31.07"/>
                        
                <line x1="37.624" x2="47.151" y1="20.309" y2="28.298"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd26" x1="34.978" x2="37.625" y1="21.272" y2="6.264"/>
                  
            <g class="bond" id="mol1bnd27">
                        
                <line x1="51.955" x2="37.625" y1="1.053" y2="6.264"/>
                        
                <line x1="51.466" x2="39.781" y1="3.825" y2="8.074"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd28" x1="51.955" x2="63.639" y1="1.053" y2="10.851"/>
                  
            <g class="bond" id="mol1bnd29">
                        
                <line x1="60.993" x2="63.639" y1="25.859" y2="10.851"/>
                        
                <line x1="58.836" x2="60.993" y1="24.049" y2="11.814"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd30" x1="46.662" x2="60.993" y1="31.07" y2="25.859"/>
                  
            <line class="bond" id="mol1bnd31" x1="44.016" x2="29.695" y1="46.079" y2="40.866"/>
                  
            <g class="bond" id="mol1bnd32">
                        
                <line x1="18.017" x2="29.695" y1="50.671" y2="40.866"/>
                        
                <line x1="17.528" x2="27.05" y1="47.898" y2="39.903"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd33" x1="18.017" x2="3.696" y1="50.671" y2="45.459"/>
                  
            <g class="bond" id="mol1bnd34">
                        
                <line x1="1.053" x2="3.696" y1="30.441" y2="45.459"/>
                        
                <line x1="3.698" x2="5.854" y1="31.404" y2="43.649"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd35" x1="1.053" x2="12.731" y1="30.441" y2="20.636"/>
                  
            <g class="bond" id="mol1bnd36">
                        
                <line x1="27.052" x2="12.731" y1="25.849" y2="20.636"/>
                        
                <line x1="24.895" x2="13.22" y1="27.658" y2="23.409"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd37" x1="29.695" x2="27.052" y1="40.866" y2="25.849"/>
                  
            <path class="atom" d="M45.957 74.925h-.721l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .357 .024 .732v2.739h-.566v-4.9h.715l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.483v-2.768h.578v4.9z" fill="#3050F8" id="mol1atm2" stroke="none"/>
                  
            <path class="atom" d="M23.415 59.274q.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q-.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM19.552 59.274q-.0 .923 .386 1.458q.393 .53 1.221 .53q.839 .0 1.22 -.53q.387 -.535 .387 -1.458q.0 -.929 -.387 -1.453q-.381 -.524 -1.208 -.524q-.834 .0 -1.227 .524q-.392 .524 -.392 1.453z" id="mol1atm5" stroke="none"/>
                  
            <path class="atom" d="M84.057 35.33h-.721l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .358 .024 .733v2.738h-.566v-4.899h.715l2.607 4.054h.03q-.006 -.107 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" fill="#3050F8" id="mol1atm9" stroke="none"/>
                  
            <path class="atom" d="M159.672 70.383q-.786 .0 -1.238 .53q-.453 .524 -.453 1.447q.0 .91 .417 1.446q.422 .53 1.268 .53q.321 .0 .607 -.054q.292 -.059 .566 -.142v.535q-.274 .102 -.566 .149q-.292 .054 -.696 .054q-.745 -.0 -1.251 -.31q-.5 -.309 -.75 -.875q-.25 -.571 -.25 -1.339q.0 -.744 .268 -1.31q.274 -.566 .804 -.881q.53 -.322 1.28 -.322q.78 .0 1.351 .286l-.244 .524q-.226 -.101 -.506 -.184q-.274 -.084 -.607 -.084zM162.428 74.806h-.601v-5.215h.601v5.215z" fill="#1FF01F" id="mol1atm21" stroke="none"/>
                  
            <g class="atom" id="mol1atm22">
                        
                <path d="M126.531 23.083q-.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.245 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q.0 -.75 .244 -1.31q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.733 .0 1.233 .316q.5 .309 .756 .875q.256 .566 .256 1.328zM122.667 23.083q.0 .922 .387 1.458q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.524 -1.209 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" stroke="none"/>
                        
                <path d="M130.837 25.535h-.619v-2.286h-2.512v2.286h-.614v-4.899h.614v2.071h2.512v-2.071h.619v4.899z" stroke="none"/>
                      
            </g>
                
            <line class="hi" id="mol1bnd1" stroke="#3050F8" x1="41.901" x2="39.1485" y1="76.137" y2="80.905"/>
            <line class="hi" id="mol1bnd2" stroke="#3050F8" x1="47.357" x2="53.3065" y1="72.475" y2="72.475"/>
            <line class="hi" id="mol1bnd3" stroke="#3050F8" x1="41.901" x2="39.1485" y1="68.813" y2="64.045"/>
            <line class="hi" id="mol1bnd8" stroke="#3050F8" x1="78.775" x2="72.8255" y1="32.88" y2="32.88"/>
            <line class="hi" id="mol1bnd9" stroke="#3050F8" x1="84.229" x2="86.9825" y1="29.218" y2="24.445"/>
            <line class="hi" id="mol1bnd14" stroke="#3050F8" x1="84.229" x2="86.9825" y1="36.543" y2="41.3155"/>
            <line class="hi" id="mol1bnd22" stroke="#1FF01F" x1="156.544" x2="152.0725" y1="70.105" y2="66.2765"/>
            <line class="hi" id="mol1bnd23" stroke="#FF0D0D" x1="121.303" x2="116.9495" y1="25.576" y2="29.228"/>
        </g>
          
    </g>
    
</svg>
","Therapeutic Uses":"Antidiarrheals","Title":"Loperamide","UNII":"6X9OC3H4II","Wikidata":"Q423751","XLogP":5}